London, UK – Myota, a pioneering London-based startup specializing in the development of advanced prebiotic fibre blends designed to significantly enhance gut health and metabolic well-being, has successfully closed a $4.5 million Series A funding round. This substantial investment, led by the prominent venture capital firm PeakBridge, is earmarked for a multi-pronged strategic expansion. Key objectives include scaling Myota’s direct-to-consumer (D2C) sales operations, establishing a robust business-to-business (B2B) division targeting the European and US markets, and further bolstering its commitment to rigorous clinical research.
The recent funding signifies a critical milestone for Myota, positioning it to capitalize on the burgeoning global demand for scientifically-backed gut health solutions. The company has already demonstrated significant traction, notably through a strategic global partnership with the popular wellness café chain Joe & The Juice, initiated last year. Further solidifying its market presence, Myota has secured supply agreements with a fast-growing brand specializing in coffee alternatives and is actively engaged in product development collaborations with several well-recognized names across the dairy, bakery, and functional beverage sectors. Its distribution network is also expanding, with existing agreements with Suannutra and Denava now covering key markets in the UK, the United States, and the European Union.
The direct-to-consumer arm of Myota experienced remarkable growth in its home market, tripling its customer base last year and surpassing the 60,000 customer threshold. This impressive D2C performance underscores the growing consumer awareness and demand for innovative gut health products.
“Most gut-health products are a marketing story built on one or two commodity fibres,” commented Yoni Glickman, Managing Partner at PeakBridge, highlighting the core differentiator of Myota’s approach. “Myota built and patented the science first and then validated the outcomes in clinical trials.” This emphasis on foundational scientific research and clinical validation is a cornerstone of Myota’s strategy and a key factor that attracted significant investor interest.
Myota’s Patented Blends: A Paradigm Shift in Prebiotic Fibre
At the heart of Myota’s innovation lies its proprietary approach to prebiotic fibre. Unlike conventional fibre supplements that often rely on a single or limited range of ingredients, Myota develops complex, patented blends. These formulations are engineered to work effectively across a diverse spectrum of individual gut microbiomes. The company’s research focuses on maximizing the production of beneficial short-chain fatty acids (SCFAs) – crucial metabolites produced by gut bacteria through the fermentation of fibre – while simultaneously minimizing the common gastrointestinal discomfort often associated with high-fibre intake.
Fibre, a vital component of a healthy diet, exists in various forms, each with distinct physiological effects. Soluble fibres, such as those found in oats and beans, dissolve in water to form a gel-like substance. This slows digestion, aids in preventing constipation, helps regulate blood glucose levels, and can contribute to lowering cholesterol. Insoluble fibres, found in whole grains and vegetables, do not dissolve and pass through the digestive system largely intact, adding bulk to stool and promoting regular bowel movements, which are essential for maintaining a healthy gut environment and supporting the gut bacteria.
Prebiotic fibres, or resistant starches, represent a specialized category. They are designed to resist digestion in the small intestine and travel to the large intestine, where they serve as a food source for beneficial gut bacteria. Myota’s scientific focus is squarely on this powerful category of nutrients.
The challenge with many existing fibre supplements, according to Myota, is their reliance on one or two standard fibres. The efficacy of a particular fibre can vary significantly from person to person due to the unique composition of their gut microbiome. Different microbiomes ferment the same fibre into SCFAs at different rates and in varying amounts, leading to inconsistent results. Myota’s patented blends are a direct response to this variability. By leveraging proprietary research and a deep understanding of microbiome science, they have created formulations designed for broad-spectrum efficacy.
This scientific platform, Myota asserts, is capable of demonstrating efficacy in gold-standard clinical trials and can be incorporated at meaningful doses into everyday food and beverage products. This combination of robust clinical backing and practical applicability is a rare and valuable proposition in the current market.
Product Portfolio and Clinical Efficacy
Myota’s product line currently offers distinct blends tailored for specific health outcomes. For consumers focused on general gut health, the company offers a blend formulated with partially hydrolyzed guar gum, gluten-free wheat and oat fibres, cellulose, guar fibre, and zinc. Clinical data suggests that within a four-week period, this blend has been effective in reducing bloating and diarrhea in 80% of users, alleviating abdominal pain or cramping in 74%, and promoting more regular bowel movements in an impressive 93% of participants.
For those seeking metabolic health benefits, Myota has developed a separate blend that combines oat and wheat fibres with fructooligosaccharides, galactooligosaccharides, inulin, soluble corn fibre, guar fibre, and zinc. Within a four-week trial period, this formulation has demonstrated significant improvements, including enhanced insulin sensitivity in 61% of consumers, a reduction in systemic inflammation in 42%, and a lowering of blood glucose responses in 28% of participants.
Both powder formulations are unflavored, allowing for seamless integration into a wide range of consumables, including water, everyday meals, and hot or cold beverages, similar to how protein powders are used. The metabolic health blend is also available in a chocolate flavor. Beyond powders, Myota also produces plant-based snack bars in apple-cinnamon and peanut butter-chocolate varieties, each offering a substantial 13 grams of fibre and 2.3 grams of protein per 50-gram serving.
The Rise of Fibre: A Key Nutrient in the Modern Health Landscape
The increased investment and focus on Myota come at a time when dietary fibre is experiencing a resurgence in prominence within the food and health industries. Fibre is increasingly being recognized as a fundamental nutrient, with a significant portion of the population in developed countries, including 95% of Brits and Americans, falling short of recommended daily intake levels.
Several converging factors are driving this heightened awareness. Documentaries exploring gut health, such as Netflix’s “Hack Your Health,” have brought the importance of the microbiome to a wider audience. Lifestyle movements like the “30-plants-a-week” challenge and online trends such as “fibremaxxing” and “fibrelayering” on platforms like TikTok are educating and engaging younger demographics about the benefits of increased fibre consumption.
Furthermore, the growing prevalence and discussion surrounding GLP-1 (Glucagon-like peptide-1) receptor agonists, commonly known as weight-loss drugs, have inadvertently amplified the focus on dietary fibre. In the UK, for example, approximately 9% of consumers have used these medications, with an additional 18% considering them. Crucially, dietary fibre can naturally stimulate the body’s own GLP-1 response. By feeding beneficial gut bacteria, fibre promotes the production of SCFAs, which play a role in regulating appetite and promoting satiety.
This connection is particularly relevant because gastrointestinal side effects are a common concern among users of GLP-1 medications. This creates a burgeoning market for companion products that can support digestive health, bolster the microbiome, and contribute to metabolic well-being. Research indicates a strong consumer desire to increase fibre intake, with 52% of British adults actively trying to consume more fibre, a figure that rises to 62% among Gen Z consumers. The perceived benefits of fibre are widely acknowledged, with most Britons recognizing its positive impact on gut health (82%), digestion (83%), and weight management (61%).
Scientific Validation and Future Outlook
Thomas Gurry, Co-founder and Chief Scientific Officer at Myota, elaborated on the company’s unique scientific approach: “We can measure how an individual’s gut bacteria ferment different fibres, and we use that to build blends that produce short-chain fatty acids reliably across very different microbiomes.” He emphasized the scientific rigor behind their claims: “Our randomized controlled trials have shown improvements in insulin sensitivity, blood sugar control, inflammation, and mood, including stress and anxiety. That evidence base is what separates a functional ingredient from a marketing claim.”
Kat Stennett, Myota’s Co-founder and CEO, underscored the transformative potential of fibre: “Fibre is among the most powerful and overlooked levers for health, and products that currently line the shelves haven’t done it justice.” She further articulated the market gap that Myota aims to fill: “What’s been missing is fibre that works across real, varied microbiomes and stands up to clinical scrutiny. That is what we’ve built, and it’s why companies across F&B, food service, and wellness are coming to us to put genuine, claimable benefits into their products. This round lets us meet that demand at scale.”
The Series A funding positions Myota to aggressively pursue its expansion plans. The establishment of a dedicated B2B sales force in Europe and the US will allow the company to forge deeper partnerships with food and beverage manufacturers, enabling them to integrate Myota’s scientifically validated prebiotic fibre blends into their product lines. Simultaneously, the investment will fuel the rapid scale-up of their D2C business, reaching a broader consumer base directly. Continued investment in clinical research will ensure Myota remains at the forefront of gut health science, validating existing products and exploring new frontiers in microbiome modulation.
The implications of this funding extend beyond Myota. It signals a growing investor confidence in the science-driven segment of the functional food and supplement market. As consumer awareness of gut health and its systemic impact on overall well-being continues to rise, companies like Myota, backed by robust scientific evidence and strategic market expansion, are poised to become leaders in shaping the future of nutrition. The successful closure of this Series A round is a testament to Myota’s innovative approach and its potential to revolutionize how we understand and utilize prebiotic fibres for enhanced health.
